<div id="readability-page-1">02:40 PM EDT, 05/15/2026 (MT Newswires) -- Wave Life Sciences ( WVE ) is expected to present new data from its RestorAATion-2 study of WVE-006 at the ATS 2026 conference that could further strengthen confidence in its RNA editing platform, Wedbush Securities said in a note Friday.The brokerage said in a Friday research note that the upcoming results could show a consistent improvement pattern versus earlier cohorts, including higher editing efficiency and sustained protein responses across dose groups.The investment firm added that the data may support clinically meaningful levels of alpha-1 antitrypsin production. It added that the durability of the response could enable monthly or less frequent dosing intervals.Wedbush has an outperform rating and a $15 price target on Wave Life Sciences ( WVE ).Shares of the company were down 2.6% in Friday trading.Price: 6.72, Change: -0.18, Percent Change: -2.61 MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

Wedbush Securities anticipates that Wave Life Sciences will present data from its RestorAATion-2 study at the ATS 2026 conference, potentially enhancing confidence in its RNA editing platform. The results may indicate improved editing efficiency and sustained protein responses, supporting alpha-1 antitrypsin production. Wedbush maintains an outperform rating with a $15 price target for Wave Life Sciences, despite a 2.6% drop in shares to $6.72.

fidelity

Wave Life Sciences

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Bioshares Biotech Clinical Trials Fd

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Wave Life Sciences ATS Data Could Support RNA Editing Platform, Wedbush Says